CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025	Jun. 30, 2024
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests		$ 2,928	$ 48	$ 5,901	$ 3,171
Foreign currency translation adjustments, net		127	(70)	(430)	70
Unrealized holding gains/(losses) on derivative financial instruments, net		(273)	127	(395)	343
Reclassification adjustments for (gains)/losses included in net income	[1]	(106)	(147)	(419)	(159)
Other comprehensive income, cash flow hedge, gain (loss), before tax, total		(379)	(21)	(814)	184
Unrealized holding gains/(losses) on available-for-sale securities, net		166	(25)	135	(77)
Reclassification adjustments for (gains)/losses included in net income	[2]	(83)	100	72	86
Other comprehensive income (loss), available-for-sale securities, before tax, total		82	74	207	9
Reclassification adjustments related to amortization of prior service costs and other, net		(24)	(28)	(55)	(56)
Reclassification adjustments related to curtailments of prior service costs and other, net		(11)	0	(44)	0
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service costs and other, before tax		(35)	(28)	(99)	(56)
Other comprehensive income/(loss), before tax		(204)	(44)	(1,136)	207
Tax provision/(benefit) on other comprehensive income/(loss)		(347)	22	(538)	76
Other comprehensive income/(loss) before allocation to noncontrolling interests		143	(67)	(598)	131
Comprehensive income/(loss) before allocation to noncontrolling interests		3,071	(19)	5,303	3,302
Less: Comprehensive income/(loss) attributable to noncontrolling interests		18	(2)	22	1
Comprehensive income/(loss) attributable to Pfizer Inc.		$ 3,053	$ (17)	$ 5,282	$ 3,302

[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.

[2] Reclassified into Other (income)/deductions—net.